Clinical Trial Update: A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tislelizumab to sorafenib for unresectable hepatocellular carcinoma has completed and posted results on 2025-10-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: COMPLETED | Results posted: 2025-10-14